



CABA

2011 CABA *Investment, Innovation & Entrepreneurship Symposium*

美中生物医药协会二〇一一投资,创新与创业研讨会

Saturday, October 8, 2011

12:00 PM – 9:00 PM

The Doubletree Guest Suites, Boston, MA

Pharma Open Innovations: Opportunities for Investors and Entrepreneurs

WWW.CABAWEB.ORG



CABA

Chinese-American BioMedical Association

美中生物医药协会



Saturday, October 8, 2011
1:00 –9:00 PM

The Doubletree Guest Suites, Boston MA
400 Soldiers Field Road, Boston, MA 02134

Presented by

Chinese-American BioMedical Association (CABA)

- 1:00PM – 1:30PM **Registration**
- 1:30PM – 1:32PM Opening
Philip Zhang, Ph.D., J.D., Conference Co-Chair
- 1:32PM – 1:45PM Welcome Address
Zhihong Chen, Ph.D., President, CABA
- Introduction of Speakers by **Jinbo Lee**, Ph.D.
- 1:45PM – 2:15PM ***Cross-border Collaboration between China and US***
Karen Wong, Ph.D., J.D., Partner, Wilson Sonsini Goodrich & Rosati LLP
- 2:15PM – 2:45PM ***Sanofi's approach to leveraging innovation in healthcare globally***
Sridaran Natesan, Ph.D., Scientific Site Head (R&D) at Sanofi-Aventis
Cambridge and Head of External Innovation and Partnering for the US Northeast
region
- 2:45PM – 3:15PM ***VC and China's Biotech***
Wei Li, Ph.D., Principal, Fidelity Bioscience Ventures
- 3:15PM – 3:30PM **Coffee Break**
- Introduction of Speakers by **Zhiyong Yang**, Ph.D.
- 3:30PM – 4:00PM ***Academic Technology Licensing and Commercialization***
Gayathri Srinivasan, Ph.D., Licensing Officer, University of Massachusetts
Medical School
- 4:00PM – 4:30PM ***Overcoming drug-resistant mutations in targeted therapy: learning from ponatinib, a pan-inhibitor of BCR-ABL for CML***
David Dalgarno, Ph.D., Vice President/Research Technologies, Ariad
Pharmaceuticals, Inc.
- 4:30PM – 5:00PM ***Career Development as an Entrepreneur***
Jean Qiu, Ph.D., Founder & President, Nexcelom Bioscience
- 5:00PM – 5:30PM **Joint Q&A**



5:30PM Close of Afternoon Program,
5:30PM – 6:30PM Cocktail Reception/Social Networking

6:30PM – 9:30PM **“Sincere Night 先声之夜”**



Sponsored by Sincere Pharmaceutical Group

6:30PM – 6:35PM Welcome Address
Yihan Wang, Ph.D.

6:45PM – 7:45PM Dinner

7:45PM – 8:30PM Evening Keynote: *Innovative R&D at China Pharma Companies: Status, Challenges and Opportunities*
Peng Wang, Ph.D., CSO, Sincere Pharmaceutical Group

8:30PM – 9:00PM Networking

Admission: CABA, CAIPLA, OCEAN, ACMA, NECINA, 128CUTE members: FREE; Non-members: \$20. On-site membership registration to CABA available. (\$20 annual membership fee due), you can also register online at www.cabaweb.org.

Parking Direction: Please enter the hotel parking garage from Storow Drive. Parking is **free**.

Conference Chair: **Philip Zhang, Ph.D., J.D.** (Milstein Zhang & Wu LLC)


Conference Co-Chairs: **Jinbo Lee, Ph.D.** (Sage Partner International); **Zhihong Chen, Ph.D.** (Eisai); **Zhiyong Yang, Ph.D.** (Pfizer)

Organizing Committee: **Zhaokui Wan, Ph.D.** (Pfizer); **Yihan Wang, Ph.D.** (Ariad Pharmaceuticals); **Zhigang Wang, Ph.D.** (Avila Therapeutics); **Fang Liu, Ph.D.** (Bonna-Agela Technologies); **Susan Qu, Ph.D.** (Genzyme); **Qinglin Che, Ph.D.** (Synta Pharmaceuticals), **Wei Zhang, Ph.D.** (Siemens Healthcare Diagnostics); **Shiwen Lin, Ph.D.** (Antigenics Inc.); **Sue Ma, Ph.D.** (Novartis)

2011 CABA Investment, Innovation & Entrepreneurship Symposium

Speakers

	<p>Sridaran Natesan, Ph.D.</p>
	<p><i>Scientific Site Head (R&D) at Sanofi-Aventis Cambridge and Head of External Innovation and Partnering for the US Northeast region</i></p>
	<p>Dr. Sridaran Natesan is the Scientific Site Head (R&D) at Sanofi-aventis in Cambridge and also the Head of External Innovation and Partnering for the US Northeast region. He is also a member of the leadership team of the Prospective Strategic Initiative group at Sanofi-aventis. From 2005-2009, he served as the co-leader of the stem cell initiative and Distinguished Scientist at Sanofi-aventis.</p> <p>Dr. Natesan received his Ph.D degree in Molecular Genetics from the University of Calgary and pursued his post-doctoral work at the Cold Spring Harbor Laboratories in New York. Dr. Natesan joined Ariad Pharmaceuticals in Cambridge, MA in 1994 as a Senior Research Scientist in its Gene Therapy Division. Later, he joined Aventis Pharmaceuticals as a Principal Scientist and led a group focused on cell based screens and stem cell biology. Dr. Natesan is one of the founding members of the Aventis Cambridge Genomics Center and played a key role in the development of the center including as its Head of the Scientific Programs and member of the senior management for several years. He also served as the Head of Molecular Pharmacology at the center during this time.</p> <p>Dr. Natesan is a member of the Industry Committee of International Society for Stem Cell Research (ISSCR). He is also member of the Outreach committee of the US India Chamber of Commerce. Dr. Natesan is responsible for setting up major academic alliances at Sanofi-aventis alliances including those with MIT and Harvard.</p>
	<p>David C. Dalgarno, Ph.D.</p>
	<p><i>Vice President, Research Technologies</i></p>
	<p>David C. Dalgarno is currently Vice President, Research Technologies at ARIAD Pharmaceuticals, Cambridge, MA. Dr. Dalgarno joined ARIAD in 1992, after a number of years as a research scientist at Schering-Plough Corporation in NJ. Dr. Dalgarno received his B.A. and D. Phil. degrees in Chemistry from the University of Oxford and received post-doctoral training at Yale University. Dr. Dalgarno currently leads an interdisciplinary group comprising of protein biochemists, structural chemists and computational chemists. His work is targeted at the interface of structural chemistry, drug design and medicinal chemistry, focusing on the design of small-molecule inhibitors of kinases and other enzymes. Dr. Dalgarno was a member of the ARIAD drug discovery teams that discovered ridaforolimus (a</p>

	<p>mTOR inhibitor), ponatinib (a BCR-ABL inhibitor) and AP26113 (an ALK/mutant EGFR inhibitor).</p>
	<p>Wei Li, Ph.D.</p>
	<p><i>Principal, Fidelity Biosciences</i></p>
	<p>Prior to joining Fidelity in 2005, Dr. Li focused his effort on healthcare and life science investment opportunities at Baird Venture Partners, the venture capital arm of R.W.Baird. Prior to Baird, he led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a small-molecule therapeutic company based in Cambridge, MA. He also worked in strategic marketing at Serono International S.A., a biopharmaceutical company based in Geneva, Switzerland. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry. Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing. Dr. Li serves on the Board of Directors of TCT Medical.</p>
	<p>Gayathri Srinivasan, Ph.D.</p>
	<p><i>Licensing Officer, University of Massachusetts Medical School</i></p>
	<p>Gayathri Srinivasan is a Licensing officer at UMass Medical School where she does licensing and commercialization of technologies that come out of UMass Medical School. She is also an executive team member for M2D2 where she helps small medical device companies with their business needs. Prior to working at UMass, Gayathri was a licensing associate at MIT's licensing office. Gayathri's background is in Microbiology. She received her Ph.D. from Ohio State University and pursued her post-doctoral work at MIT.</p>
	<p>Karen Wong, Ph.D., J.D.</p>
	<p><i>Partner, Wilson Sonsini Goodrich & Rosati</i></p>
	<p>Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom-to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.</p>

	<p>Concentrating on cutting-edge biotechnology, Karen focuses her multidisciplinary practice on a combination of molecular biology, optical physics, chemical engineering, pharmacology, molecular diagnostics, and cellular physiology. She has developed technical expertise in DNA-sequencing techniques and instruments, antibody engineering and design, biofuels, drug delivery systems, gene therapies, cancer treatments, and point-of-care diagnostic tools.</p> <p>Prior to practicing law, Karen conducted doctoral and post-doctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology.</p> <p>Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.</p>
	<p>Jean Qiu, Ph.D.</p> <p>Founder and President, Nexcelom Bioscience LLC</p> <p>Dr. Jean Qiu is the founder and President of Nexcelom Bioscience LLC. From the basement of her home, she started the company in 2003, with the goal of automating manual cell counting and analysis on the biologist’s lab bench. Today, the Cellometer-branded cell counting systems, consisting of instrument, software and consumables, are distributed globally and used in laboratories of pharmaceutical companies, government institutions and universities for biomedical research, such as cancer research, vaccine development and drug discovery. The company has now grown to nearly 30 people in Lawrence, Massachusetts, where the dedicated entrepreneurial team covers everything from engineering and manufacturing to marketing and customer service.</p> <p>Prior to Nexcelom Bioscience, Dr. Qiu worked for 3M Company for more than a decade, as a product commercialization team leader in Health Care Group, Research Specialist in the Material Application Laboratory, and Senior Research Engineer in the Corporate Research Laboratory, where she was a co-inventor of the first blue-green semiconductor laser. She also worked for a biotech start-up, as its Director of Process Development and Manufacturing, where she developed plastic optical sensors and established its manufacturing process.</p> <p>Dr. Qiu earned her PhD in Electrical Engineering from Purdue University in 1990 and her BS in Electrical Engineering from Nanjing Institute of Technology in China. She has published numerous papers in peer-reviewed academic journals and holds 23 US patents. Awards received include the Rank Prize for Opto-Electronics, London, UK, 1993, for the invention of the blue-green diode laser, and 3M Company’s Excellent Record of Invention Award. In 2006, Dr. Qiu was honored by the Boston Woman’s Business Journal with the Hall of</p>

	Fame Award.
	Peng Wang, Ph.D.
	<i>CSO, Sincere Pharmaceutical Group</i>
	Dr. Peng Wang is currently Chief Scientific Officer and Vice President of Sincere Pharmaceuticals Group (sincere.com; “SCR” at NYSE). Prior to joining Sincere, Dr. Wang was with WuXi PharmaTech (“WX” at NYSE), a leading pharmaceutical CRO in China, as Vice President of Discovery Biology and a member of the company’s Standing Executive Committee. Prior to joining WuXi PharmaTech, Dr. Wang worked for Schering-Plough Research Institute in New Jersey, USA for 18 years. Dr. Wang made significant contributions to discovery and early development of several drug candidates as a Discovery Team Co-chair and/or biology leader. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo, and his B.S. in medicinal chemistry from the China Pharmaceutical University.

Event Sponsors



Exhibitors

